The Effect of WT-1 Positivity on Survival Outcomes in Patients with High-grade Serous Epithelial Ovarian Cancer

被引:0
作者
Karakas, Sema [1 ]
Tunca, Aysun Fendal [1 ]
Altinay, Serdar [2 ]
Yildiz, Gunes Ozlem [3 ]
Ekin, Murat [1 ]
机构
[1] Univ Hlth Sci Turkey, Bakirkoy Dr Sadi Konuk Training & Res Hosp, Clin Gynecol & Obstet, Istanbul, Turkey
[2] Univ Hlth Sci Turkey, Istanbul Haseki Training & Res Hosp, Clin Pathol, Istanbul, Turkey
[3] Univ Hlth Sci Turkey, Bakirkoy Dr Sadi Konuk Training & Res Hosp, Clin Anesthesiol & Reanimat, Istanbul, Turkey
关键词
Ovarian cancer; prognosis; survival; tumor marker; SWT-1; TUMOR GENE WT1; WILMS-TUMOR; FALLOPIAN-TUBE; MUCINOUS CARCINOMAS; CLEAR-CELL; EXPRESSION; IMMUNOREACTIVITY; PERITONEUM; BREAST; PANEL;
D O I
10.4274/BMJ.galenos.2022.2022.1-16
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective: This study investigated the significance WT-1 positivity on survival outcomes in patients with high-grade serous epithelial ovarian cancer (HGSOC). Methods: The medical records of the women who underwent surgery due to HGSOC between January 2015 and January 2020 were recorded. The patients' basic characteristic, serum tumor markers, disease stage, chemotherapeutic response, overall survival (OS), and progression-free survival (PFS) were recorded. WT-1 immune-staining was performed for all tissue samples. Results: The median age of the patients in the WT-1 (+) group was 59 (40-88) years, and it was 52 (41-78) in the WT-1 (-) group that was significantly higher in the WT-1 (+) group (p=0.007). The median Ca125 level was significantly higher in the WT-1 (+) group than the WT-1 (-) group [634 (7-12,580) vs. 274 (12-2,856), p=0.03]. The PFS [22 (8-54) vs. 12 (0-48), p<0.001] and OS [30 (8-56) vs. 16 (2-70), p<0.001] rates were significantly higher in the WT-1 (-) group than the WT-1 (+) group in Cox regression analysis, Ca125 was significantly associated with OS in univariate analysis (HR:1, 95% confidence interval:1-1.001, p=0.005). Conclusion: The patients with WT-1 positivity was associated with significantly shorter PFS and OS. Besides the patients in the WT-1 (+) group was older and had higher Ca125 levels than the WT-1 (-) group. The number of postmenopausal patients was higher in the WT-1 (+) group.
引用
收藏
页码:151 / 156
页数:6
相关论文
共 17 条
[1]   WT1 is differentially expressed in serous, endometrioid, clear cell, and mucinous carcinomas of the peritoneum, fallopian tube, ovary, and endometrium [J].
Acs, G ;
Pasha, T ;
Zhang, PJ .
INTERNATIONAL JOURNAL OF GYNECOLOGICAL PATHOLOGY, 2004, 23 (02) :110-118
[2]   WT-1 assists in distinguishing ovarian from uterine serous carcinoma and in distinguishing between serous and endometrioid ovarian carcinoma [J].
Al-Hussaini, M ;
Stockman, A ;
Foster, H ;
McCluggage, WG .
HISTOPATHOLOGY, 2004, 44 (02) :109-115
[3]   Expression of the Wilms' tumour gene WT1 in the developing human and in paediatric renal tumours: An immunohistochemical study [J].
Charles, AK ;
Mall, S ;
Watson, J ;
Berry, PJ .
JOURNAL OF CLINICAL PATHOLOGY-MOLECULAR PATHOLOGY, 1997, 50 (03) :138-144
[4]  
Goldstein NS, 2002, AM J CLIN PATHOL, V117, P541
[5]  
Goldstein NS, 2001, AM J CLIN PATHOL, V116, P246
[6]   Wilms tumor gene immunoreactivity in primary serous carcinomas of the fallopian tube, ovary, endometrium, and peritoneum [J].
Hashi, A ;
Yuminamochi, T ;
Murata, SI ;
Iwamoto, H ;
Honda, T ;
Hoshi, K .
INTERNATIONAL JOURNAL OF GYNECOLOGICAL PATHOLOGY, 2003, 22 (04) :374-377
[7]   Expression of Wilms tumor gene (WT1) in epithelial ovarian cancer [J].
Hylander, B ;
Repasky, E ;
Shrikant, P ;
Intengan, M ;
Beck, A ;
Driscoll, D ;
Singhal, P ;
Lele, S ;
Odunsi, K .
GYNECOLOGIC ONCOLOGY, 2006, 101 (01) :12-17
[8]   WT1, estrogen receptor, and progesterone receptor as markers for breast or ovarian primary sites in metastatic adenocarcinoma to body fluids [J].
Lee, BH ;
Hecht, JL ;
Pinkus, JL ;
Pinkus, GS .
AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 2002, 117 (05) :745-750
[9]  
Miyoshi Y, 2002, CLIN CANCER RES, V8, P1167
[10]   Cancer immunology-analysis of host and tumor factors for personalized medicine [J].
Ogino, Shuji ;
Galon, Jerome ;
Fuchs, Charles S. ;
Dranoff, Glenn .
NATURE REVIEWS CLINICAL ONCOLOGY, 2011, 8 (12) :711-719